Apolipoprotein E gene polymorphism alters lipids before pancreas transplantation

Sajeev Balakrishnan, Christopher Colling, Tab Burkman, Judi Erickson, Elizabeth Lyden, Hiralal Maheshwari, Lynn R Mack, James Lane, Jennifer Lynn Larsen

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background. Pancreas transplantation (PTX) improves lipids in patients with type 1 diabetes mellitus. However, there are patients who have persistent abnormal lipids or develop new hyperlipidemia despite PTX. One factor that may influence the lipid profile is apolipoprotein E (Apo E) genotype. Apo E polymorphism, particularly E2 and E4 alleles, increases the risk of dyslipidemia. Apo E2 has also been found to increase risk of diabetic nephropathy and so may be more prevalent in PTX candidates. Methods. This study evaluated fasting-lipid profiles in type I 1 diabetes patients who were pancreas transplant candidates to prospectively evaluate the impact of Apo E genotype on dyslipidemia before and after PTX. Results. Presence of one or more E4 alleles resulted in higher triglycerides (P=0.0446), lower HDL (P=0.0247), and a higher cholesterol-to-HDL (C/H) ratio (P=0.0405) before PTX when compared with those with E3/3 genotype. After PTX, lipids improved so there was no longer a difference in fasting lipids between patients with an E4 allele and E3/3 genotype. Presence of an E2 allele had no significant impact on fasting lipids before or after PTX. Conclusions. Presence of an Apo E4 allele worsened HDL, triglycerides, and C/H ratio before PTX compared with those with E3/3 genotype, whereas the presence of an Apo E2 allele had no significant effect on lipids before or after PTX. Thus, Apo E4 has a larger impact than Apo E2 on fasting-lipid profile in PTX candidates, and Apo E gene polymorphism does not worsen lipid dyslipidemia after PTX, despite introduction of immunosuppressant medications known to cause dyslipidemia.

Original languageEnglish (US)
Pages (from-to)974-977
Number of pages4
JournalTransplantation
Volume74
Issue number7
DOIs
StatePublished - Oct 15 2002

Fingerprint

Pancreas Transplantation
Apolipoproteins E
Lipids
Genes
Alleles
Apolipoprotein E2
Dyslipidemias
Genotype
Fasting
Apolipoprotein E4
Type 1 Diabetes Mellitus
HDL Cholesterol
Triglycerides
Diabetic Nephropathies
Immunosuppressive Agents
Hyperlipidemias
Pancreas
Transplants

ASJC Scopus subject areas

  • Transplantation

Cite this

Balakrishnan, S., Colling, C., Burkman, T., Erickson, J., Lyden, E., Maheshwari, H., ... Larsen, J. L. (2002). Apolipoprotein E gene polymorphism alters lipids before pancreas transplantation. Transplantation, 74(7), 974-977. https://doi.org/10.1097/00007890-200210150-00013

Apolipoprotein E gene polymorphism alters lipids before pancreas transplantation. / Balakrishnan, Sajeev; Colling, Christopher; Burkman, Tab; Erickson, Judi; Lyden, Elizabeth; Maheshwari, Hiralal; Mack, Lynn R; Lane, James; Larsen, Jennifer Lynn.

In: Transplantation, Vol. 74, No. 7, 15.10.2002, p. 974-977.

Research output: Contribution to journalArticle

Balakrishnan, S, Colling, C, Burkman, T, Erickson, J, Lyden, E, Maheshwari, H, Mack, LR, Lane, J & Larsen, JL 2002, 'Apolipoprotein E gene polymorphism alters lipids before pancreas transplantation', Transplantation, vol. 74, no. 7, pp. 974-977. https://doi.org/10.1097/00007890-200210150-00013
Balakrishnan S, Colling C, Burkman T, Erickson J, Lyden E, Maheshwari H et al. Apolipoprotein E gene polymorphism alters lipids before pancreas transplantation. Transplantation. 2002 Oct 15;74(7):974-977. https://doi.org/10.1097/00007890-200210150-00013
Balakrishnan, Sajeev ; Colling, Christopher ; Burkman, Tab ; Erickson, Judi ; Lyden, Elizabeth ; Maheshwari, Hiralal ; Mack, Lynn R ; Lane, James ; Larsen, Jennifer Lynn. / Apolipoprotein E gene polymorphism alters lipids before pancreas transplantation. In: Transplantation. 2002 ; Vol. 74, No. 7. pp. 974-977.
@article{5f1dd71c13564fcda98e9c3978abc97b,
title = "Apolipoprotein E gene polymorphism alters lipids before pancreas transplantation",
abstract = "Background. Pancreas transplantation (PTX) improves lipids in patients with type 1 diabetes mellitus. However, there are patients who have persistent abnormal lipids or develop new hyperlipidemia despite PTX. One factor that may influence the lipid profile is apolipoprotein E (Apo E) genotype. Apo E polymorphism, particularly E2 and E4 alleles, increases the risk of dyslipidemia. Apo E2 has also been found to increase risk of diabetic nephropathy and so may be more prevalent in PTX candidates. Methods. This study evaluated fasting-lipid profiles in type I 1 diabetes patients who were pancreas transplant candidates to prospectively evaluate the impact of Apo E genotype on dyslipidemia before and after PTX. Results. Presence of one or more E4 alleles resulted in higher triglycerides (P=0.0446), lower HDL (P=0.0247), and a higher cholesterol-to-HDL (C/H) ratio (P=0.0405) before PTX when compared with those with E3/3 genotype. After PTX, lipids improved so there was no longer a difference in fasting lipids between patients with an E4 allele and E3/3 genotype. Presence of an E2 allele had no significant impact on fasting lipids before or after PTX. Conclusions. Presence of an Apo E4 allele worsened HDL, triglycerides, and C/H ratio before PTX compared with those with E3/3 genotype, whereas the presence of an Apo E2 allele had no significant effect on lipids before or after PTX. Thus, Apo E4 has a larger impact than Apo E2 on fasting-lipid profile in PTX candidates, and Apo E gene polymorphism does not worsen lipid dyslipidemia after PTX, despite introduction of immunosuppressant medications known to cause dyslipidemia.",
author = "Sajeev Balakrishnan and Christopher Colling and Tab Burkman and Judi Erickson and Elizabeth Lyden and Hiralal Maheshwari and Mack, {Lynn R} and James Lane and Larsen, {Jennifer Lynn}",
year = "2002",
month = "10",
day = "15",
doi = "10.1097/00007890-200210150-00013",
language = "English (US)",
volume = "74",
pages = "974--977",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Apolipoprotein E gene polymorphism alters lipids before pancreas transplantation

AU - Balakrishnan, Sajeev

AU - Colling, Christopher

AU - Burkman, Tab

AU - Erickson, Judi

AU - Lyden, Elizabeth

AU - Maheshwari, Hiralal

AU - Mack, Lynn R

AU - Lane, James

AU - Larsen, Jennifer Lynn

PY - 2002/10/15

Y1 - 2002/10/15

N2 - Background. Pancreas transplantation (PTX) improves lipids in patients with type 1 diabetes mellitus. However, there are patients who have persistent abnormal lipids or develop new hyperlipidemia despite PTX. One factor that may influence the lipid profile is apolipoprotein E (Apo E) genotype. Apo E polymorphism, particularly E2 and E4 alleles, increases the risk of dyslipidemia. Apo E2 has also been found to increase risk of diabetic nephropathy and so may be more prevalent in PTX candidates. Methods. This study evaluated fasting-lipid profiles in type I 1 diabetes patients who were pancreas transplant candidates to prospectively evaluate the impact of Apo E genotype on dyslipidemia before and after PTX. Results. Presence of one or more E4 alleles resulted in higher triglycerides (P=0.0446), lower HDL (P=0.0247), and a higher cholesterol-to-HDL (C/H) ratio (P=0.0405) before PTX when compared with those with E3/3 genotype. After PTX, lipids improved so there was no longer a difference in fasting lipids between patients with an E4 allele and E3/3 genotype. Presence of an E2 allele had no significant impact on fasting lipids before or after PTX. Conclusions. Presence of an Apo E4 allele worsened HDL, triglycerides, and C/H ratio before PTX compared with those with E3/3 genotype, whereas the presence of an Apo E2 allele had no significant effect on lipids before or after PTX. Thus, Apo E4 has a larger impact than Apo E2 on fasting-lipid profile in PTX candidates, and Apo E gene polymorphism does not worsen lipid dyslipidemia after PTX, despite introduction of immunosuppressant medications known to cause dyslipidemia.

AB - Background. Pancreas transplantation (PTX) improves lipids in patients with type 1 diabetes mellitus. However, there are patients who have persistent abnormal lipids or develop new hyperlipidemia despite PTX. One factor that may influence the lipid profile is apolipoprotein E (Apo E) genotype. Apo E polymorphism, particularly E2 and E4 alleles, increases the risk of dyslipidemia. Apo E2 has also been found to increase risk of diabetic nephropathy and so may be more prevalent in PTX candidates. Methods. This study evaluated fasting-lipid profiles in type I 1 diabetes patients who were pancreas transplant candidates to prospectively evaluate the impact of Apo E genotype on dyslipidemia before and after PTX. Results. Presence of one or more E4 alleles resulted in higher triglycerides (P=0.0446), lower HDL (P=0.0247), and a higher cholesterol-to-HDL (C/H) ratio (P=0.0405) before PTX when compared with those with E3/3 genotype. After PTX, lipids improved so there was no longer a difference in fasting lipids between patients with an E4 allele and E3/3 genotype. Presence of an E2 allele had no significant impact on fasting lipids before or after PTX. Conclusions. Presence of an Apo E4 allele worsened HDL, triglycerides, and C/H ratio before PTX compared with those with E3/3 genotype, whereas the presence of an Apo E2 allele had no significant effect on lipids before or after PTX. Thus, Apo E4 has a larger impact than Apo E2 on fasting-lipid profile in PTX candidates, and Apo E gene polymorphism does not worsen lipid dyslipidemia after PTX, despite introduction of immunosuppressant medications known to cause dyslipidemia.

UR - http://www.scopus.com/inward/record.url?scp=0037108833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037108833&partnerID=8YFLogxK

U2 - 10.1097/00007890-200210150-00013

DO - 10.1097/00007890-200210150-00013

M3 - Article

VL - 74

SP - 974

EP - 977

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 7

ER -